Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating.
Why Grail Stock Is Sinking Friday GRAIL (
NASDAQ: GRAL ) shares plunged after the NHS-Galleri trial failed to meet its primary endpoint. Explore the trial results.
Here's Why This Exciting Healthcare Stock Popped 13% Today Investors are getting excited by the prospects for Grail's Galleri test in 2026.
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an ambitious price target of $105.00. The move comes as the liquid biopsy pioneer reported preliminary full-year 2025 financial
Here's Why Grail Soared, Again, in November A combination of operational improvements and developments at its key rival bolstered the stock recently.
Why Grail Stock Zoomed Nearly 7% Higher on Monday The company has significant potential with its comprehensive cancer test.
GRAIL INC (NASDAQ:GRAL) Q3 2025 Earnings: Tops Revenue and EPS Estimates as Galleri Sales Climb GRAIL (GRAL) Q3 2025 earnings beat estimates on revenue and EPS, sending the stock higher. Strong growth for its Galleri cancer test drove the positive results.
Here's Why Grail Stock Exploded Higher by 55% in October The company demonstrated tangible progress on its path to profitability.
Why Is GRAL Stock Rising Today? GRAIL plans to raise about $325 million through a private placement involving both new and existing institutional investors.
Why Grail Stock Soared 14% Higher on Thursday The company is receiving a significant equity investment as a component of a collaboration agreement with a large business partner.
